http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020230266-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_53301eed6768a437eeb5cfadc640888a
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1096
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1069
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1078
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-10
filingDate 2018-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1600d00682e7c74dd804ff36be330b9d
publicationDate 2020-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2020230266-A1
titleOfInvention The optimal 225actinium--213bismuth generator for alpha-particle radioimmunotherapy
abstract The present invention is directed to a method for the preparation of a radiolabled conjugate composition comprising Bismuth-213 loaded targeting moieties that have been diluted with cold targeting moieties in a predetermined ratio of amount of cold targeting moieties to amount of Bismuth-213 loaded targeting moieties. Said ratio is determined by determining the amount T of target moieties per diseased cell to be treated, and determining the amount Z of Bismuth-213 atoms needed to kill a diseased cell, and contacting targeting moieties with Bismuth-213 atoms in a ratio of T over Z, to form a conjugate composition with a predetermined ratio of cold targeting moieties and Bismuth-213 loaded targeting moieties. The invention is further directed to a conjugate that can be prepared with the method according to the invention, a pharmaceutical formulation comprising the conjugate according to the invention.
priorityDate 2017-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6335500
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226896319
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP00634
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426099727
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10009010
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419586411
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6337093
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP02879
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ05205
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6230
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID167045
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6337078
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415861062
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419577473
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP81800
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3053
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID145958
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419578835
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23965
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415850380
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426099714
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226407258
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226412118
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9085
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP19147
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP83456
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP21948
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP86348
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP84122
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ05700
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCO60109
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426099534

Total number of triples: 47.